Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07456800 · ClinicalTrials.gov registry record · Phase 1
PK of Deupirfenidone Versus Pirfenidone in Older Healthy Subjects
A Phase 1 study, sponsored by PureTech.
- Completed
- Registry status
- Phase 1
- Development phase
- 116
- Enrollment target
NCT07456800: Completed Phase 1 study, sponsored by PureTech.
NCT07456800 is a Phase 1 study that has completed, run by PureTech. The registered enrollment target is 116 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (93% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07456800, a Phase 1 study, has completed, sponsored by PureTech.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 116 participants
- Enrollment target
Study Summary
A three-part, randomized, double-blind study in healthy older adults to identify a dose of deupirfenidone for further clinical study.
Primary Outcome
To compare the Cmax of 850 mg BID dosing of deupirfenidone to 801 mg TID dosing of pirfenidone at steady state, in older healthy subjects, when administered in a two-period crossover design.
Interventions
- DRUG Placebo
- DRUG Deupirfenidone
- DRUG Pirfenidone (PFD)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116 participants |
| Start Date | 2021-07-12 |
| Est. Completion | 2022-01-20 |
| Phase | Phase 1 |
What the finished NCT07456800 record still lists
NCT07456800 is an interventional study that assigns participants to a tested intervention. The registered 116 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (93% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT07456800 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07456800 about?
NCT07456800 is a clinical study titled "PK of Deupirfenidone Versus Pirfenidone in Older Healthy Subjects". A three-part, randomized, double-blind study in healthy older adults to identify a dose of deupirfenidone for further clinical study.
What is the current status of trial NCT07456800?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 116 participants. The study started on 2021-07-12. Estimated completion is 2022-01-20.
What interventions are being tested in trial NCT07456800?
The interventions under investigation include: Placebo (DRUG), Deupirfenidone (DRUG), Pirfenidone (PFD) (DRUG).
Who is sponsoring clinical trial NCT07456800?
This trial is sponsored by PureTech, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07456800's enrollment target sits among peer trials
116 501st of 2000 higher than 1,497 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03014687 · 116 participants · Phase 4
Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions
- NCT03214562 · 116 participants · Phase 1
Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia
- NCT03847467 · 116 participants · Phase 1
Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF Therapy
- NCT04222413 · 116 participants · Phase 1
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI